Lv4
490 积分 2024-01-04 加入
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
3天前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
3天前
已完结
Effect of Neoadjuvant Endocrine Therapy (Combined Androgen Blockade) on Normal Prostate and Prostatic Carcinoma
22天前
已完结
MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT
1个月前
已完结
Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1
1个月前
已完结
A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy
1个月前
已完结
Rezvilutamide: First Approval
2个月前
已完结
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
2个月前
已完结
Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta‐analysis
2个月前
已完结
Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta‐analysis
2个月前
已完结
皖公网安备34019202002308
